Menarini Stemline

Executive Director, Clinical Assessment and Evaluation, Solid Tumor Clinical Development

This role is responsible for translating pre-clinical and early clinical oncology data into high-value clinical development plans and evaluating emerging modalities for clinical success and regulatory approval. It also supports business development through due diligence, asset evaluation, and competitive intelligence across the oncology landscape.

Key Responsibilities
  • • Supporting business development opportunities at pre-clinical and clinical stages
  • • Translating pre-clinical and early clinical oncology data into prospective, high-value clinical development plans
  • • Evaluating emerging modalities to determine their potential for clinical success and regulatory approval
  • • Possess a deep-seated understanding of the current and emerging oncology landscape across the full spectrum of solid tumor malignancies (including GI, Thoracic, GU, etc.)
  • • Lead the design of comprehensive Clinical Development Plans that bridge the gap from preclinical "Proof of Concept" to registrational success, ensuring every trial phase is optimized for speed and statistical significance
  • • Draft high-level innovative trial designs (e.g., umbrella, basket, or adaptive trials) for first-in-class assets to efficiently evaluate novel mechanisms of action (MoA)
  • • Use scientific and market data to determine which oncology indications offer the highest probability of success
  • • Provide clinical perspective on in-licensing opportunities, from early-stage platforms to late-stage assets
  • • Develop and maintain TPPs for potential assets, ensuring they align with unmet medical needs and have a clear path to regulatory approval
  • • Perform rigorous biological and clinical pressure-testing to every potential in-license opportunity and how it fits into the competitive landscape
  • • Forecast the 5–10-year oncology landscape to align our assets with future shifts in the standard of care
  • • Attend major global summits (AACR, ASCO, ESMO, SABCS), to monitor oncology trends and emerging landscape changes
  • • Maintain a network of world-class oncology Key Opinion Leaders to stress-test clinical hypotheses and development strategies
Required
  • • MD is mandatory
  • • 12+ years of progressive experience in Clinical Development within biotech or pharma
  • • Possess and maintain a deep knowledge of the oncology landscape across solid tumors and a demonstrated ability to predict which scientific trends will yield clinical success
  • • Ability to interpret complex biomarker data, PK/PD modeling, and high-level biostatistical output
  • • A deep professional network within the oncology scientific community
  • • Proven experience in scientific due diligence for M&A or licensing deals
  • • Confidence to act decisively and make strategic decisions
  • • Deep familiarity with FDA/EMA oncology guidance, including expedited pathways (Breakthrough Therapy, Fast Track, RMAT)
Preferred
  • • a PhD and/or MBA is highly desirable
  • • Board certification in Oncology or Hematology is a plus

The Executive Director, Clinical Assessment & Evaluation is a physician responsible for supporting business development opportunities at pre-clinical and clinical stages, tasked with translating pre-clinical and early clinical oncology data into prospective, high-value clinical development plans. A key responsibility will be evaluating emerging modalities to determine their potential for clinical success and regulatory approval. Our mission is to build a portfolio of first-in-class assets that redefine the standard of care.



Clinical Development Architectur

  • eComprehensive Clinical Foundation: Possess a deep-seated understanding of the current and emerging oncology landscape across the full spectrum of solid tumor malignancies (including GI, Thoracic, GU, etc.
  • )End-to-End Strategic Design: Lead the design of comprehensive Clinical Development Plans that bridge the gap from preclinical "Proof of Concept" to registrational success, ensuring every trial phase is optimized for speed and statistical significance
  • .Novel Design Conceptualization: Draft high-level innovative trial designs (e.g., umbrella, basket, or adaptive trials) for first-in-class assets to efficiently evaluate novel mechanisms of action (MoA)
  • .Indication Prioritization: Use scientific and market data to determine which oncology indications offer the highest probability of success

.Due Diligence & Asset Evaluatio

  • nClinical Evaluation: Provide clinical perspective on in-licensing opportunities, from early-stage platforms to late-stage assets
  • .Target Product Profiles (TPP): Develop and maintain TPPs for potential assets, ensuring they align with unmet medical needs and have a clear path to regulatory approval
  • .MoA Gatekeeping: Perform rigorous biological and clinical pressure-testing to every potential in-license opportunity and how it fits into the competitive landscape

.Competitive Intelligenc

  • eAnticipatory Analysis: Forecast the 5–10-year oncology landscape to align our assets with future shifts in the standard of care
  • .Conference Representation: Attend major global summits (AACR, ASCO, ESMO, SABCS), to monitor oncology trends and emerging landscape changes
  • .KOL Network: Maintain a network of world-class oncology Key Opinion Leaders to stress-test clinical hypotheses and development strategies


.
Educatio

  • n:MD is mandator
  • y.Additionally, a PhD and/or MBA is highly desirabl
  • e.Board certification in Oncology or Hematology is a plu
  • s.Experience: 12+ years of progressive experience in Clinical Development within biotech or pharm
  • a.Possess and maintain a deep knowledge of the oncology landscape across solid tumors and a demonstrated ability to predict which scientific trends will yield clinical succes
  • s.Ability to interpret complex biomarker data, PK/PD modeling, and high-level biostatistical output
  • s.A deep professional network within the oncology scientific communit
  • y.Proven experience in scientific due diligence for M&A or licensing deals. Confidence to act decisively and make strategic decision
  • s.Deep familiarity with FDA/EMA oncology guidance, including expedited pathways (Breakthrough Therapy, Fast Track, RMAT

)

. NOTE: Expectations for business travel and onsite presence approx. 15%. While this position may be done remotely from anywhere in the US, the position is classified as a corporate office position. In accordance with the New York state employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotel


y.
Keep track of your job search

Save personal notes for each job to track your thoughts, application status, and follow-ups.

Try for free
Upload your resume

Sign up to upload your resume and get AI-powered customization for job applications.

Sign up free
Practice your interview

Get AI-powered mock interviews tailored to this Executive Director, Clinical Assessment and Evaluation, Solid Tumor Clinical Development role. Upload your resume and practice with real-time voice feedback.

Sign up to practice
Sign up required

Please sign up or log in to apply to this opportunity.

Mozibox
Join Mozibox
Get physician jobs matched to you

Create an account to continue applying and see more relevant roles.

Current job

OR

Already have an account? Log in

Report issue

Help us improve job quality.

This information helps us improve job accuracy.
We may follow up with you about this report.
Job Actions